OBJECTIVE: To evaluate the applicability of immune-related response criteria (irRC) in treating @entity1149 ( @entity1149 ) by @entity1058 ( @entity1058 ). METHODS: Totally 97 stage III a-IV @entity1149 @entity1 were predominantly treated with comprehensive @entity1058 . Curative effects were evaluated by three methods such as Response Evaluation Criteria in @entity5 (RECIST), Oncologic Curative Effect Evaluation Criteria of Chinese Medicine in @entity5 (draft, abbreviated as @entity1058 criteria), and irRC. The correspondency and consistency between irRC, RECIST and @entity1058 criteria were analyzed and compared. The objectivity of irRC in evaluating curative effect of Chinese medical treatment for @entity1149 was assessed. RESULTS: The correspondency rate of irRC to RECIST was 59. 79% with Kappa value of 0. 379 (U test, P <0. 01). The two criteria had certain correspondence, but with an unsatisfactory consistency. The correspondency rate of irRC to @entity1058 criteria rate was 83. 51% with Kappa value of 0.751 (U test, P <0. 01). The two criteria had good correspondence and consistency. CONCLUSIONS: @entity1058 criteria had good consistency with @entity1058 criteria in evaluating curative effect for Chinese medical treatment of advanced @entity1149 . Its results could objectively reflect features and advantages of @entity1058 for treating advanced @entity1149 .

[Clinical Application of Immune-related Response Criteria in Evaluating Chinese Medical Treatme for Advanced XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Solid Tumors', 'Solid Tumor'] @entity1058 :: ('MESH:C562377', 'Disease') :: ['Chinese medicine', 'CM']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-small Cell Lung Cancer']
